LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF)
, a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has partnered with Ethos Discovery to expand the test menu options that can be run on the company’s proprietary MiQLab(TM) System. The initial MiQLab offering, the Bacterial and AMR Test, is designed to aid in diagnosing urinary tract infections (“UTI”), which is one of the most common problems behind veterinary visits in companion animals. The MiQLab panel detects 94% of the pathogens that cause UTI in cats and dogs; the panel also screens for 13 different antimicrobial resistance targets that help to identify the best treatment for the UTI. An early adopter of the MiQLab technology, Ethos Discovery was impressed with the coverage of tests included in LexaGene’s first validated panel and indicated interest in working with LexaGene in expanding use cases for the MiQLab to help in the diagnosis of other disease conditions, including sepsis, effusions, chronic/complicated wounds, pneumonia, diarrhea, joint diseases, seizures, hemangiosarcoma and tick-borne infections. “Expanding our test menu is one of our priorities that will drive sales,” said LexaGene founder and CEO Dr. Jack Regan in the press release. “It is very important for LexaGene to continually invest in developing new tests so that the MiQLab can be used as a valued point of care instrument that can serve a diversity of unmet needs in veterinary medicine. I’m thrilled to work with Ethos Discovery on further expanding the utility of the MiQLab system. Collaborations like this will result in many more sales in the future, as the value proposition for adopting MiQLab increasingly becomes an obvious choice.”
To view the full press release, visit https://ibn.fm/ARIWU
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. LexaGene’s MiQLab(TM) system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com
NOTE TO INVESTORS:
The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.